Feds build biodata hub, but industry gets the keys

What it does

This bill establishes a centralized federal database called the Web of Biological Data, managed by the Department of Energy through a National Laboratory, to aggregate biological research data funded by the government and make it accessible to researchers via a single online portal. The system will use artificial intelligence and advanced computational tools to organize and analyze the data, with phased rollout over 5 years and $420 million in initial funding, while maintaining cybersecurity protections and restricting access from certain countries.

Why we flagged it

The bill's core function is establishing a federally funded, centralized biological data repository to serve researchers and advance scientific discovery. While it involves industry partnerships and AI integration, the primary mechanism is a public-sector research infrastructure project, not a corporate subsidy or deregulation.

What the text implies

• Industry members gain structured access to federally funded biological datasets through the advisory board (4 of 11 seats) and cost-sharing partnerships, potentially creating competitive advantage for private biotech firms without explicit data-licensing restrictions.
• The bill restricts data sharing with certain countries 'as determined by Secretary' — a broad discretionary power that could be weaponized for geopolitical purposes or create barriers to international scientific collaboration.
• Tiered cybersecurity and access controls may create a two-tier research system where well-resourced institutions and industry partners gain faster/fuller access than smaller academic labs or public researchers.
• The advisory board is explicitly exempted from the Federal Advisory Committee Act (FACA), removing transparency requirements for how industry influence shapes the platform's design and data-access policies.
• AI training on biological data hosted in the Web may generate proprietary models and insights that private companies can commercialize without explicit benefit-sharing with the public or original data contributors.

Who it affects

The bill creates a public research infrastructure that consolidates federally funded biological data, reducing duplication and accelerating scientific discovery that benefits public health and medical research. Citizens gain improved access to taxpayer-funded research outputs, though the bill includes security restrictions and industry involvement that warrant monitoring for potential data-access imbalances.

Who stands to gain

• biotechnology companies
• pharmaceutical firms
• AI/machine learning vendors
• National Laboratories (grant recipients)
• academic research institutions

Named in the bill

Department of Energy (DOE), National Laboratory, National Institute of Standards and Technology (NIST), National Science Foundation (NSF), National Library of Medicine, National Center for Biotechnology Information (NCBI), House Committee on Science, Space, and Technology, Senate Committee on Energy and Natural Resources, biotechnology industry, Federal Advisory Committee Act (FACA)

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Jun 11, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 11, 2026 — Referred to House Committee on Science, Space, and Technology · Congress.gov: “Referred to the House Committee on Science, Space, and Technology”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.